Parkworth Wealth Management, Inc. Summit Therapeutics Inc. Transaction History
Parkworth Wealth Management, Inc.
- $125 Billion
- Q1 2025
A detailed history of Parkworth Wealth Management, Inc. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Parkworth Wealth Management, Inc. holds 4 shares of SMMT stock, worth $97. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4Holding current value
$97% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SMMT
# of Institutions
237Shares Held
86.8MCall Options Held
1.84MPut Options Held
3.13M-
Baker Bros. Advisors LP New York, NY24.4MShares$593 Million5.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.6MShares$283 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$192 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$159 Million0.02% of portfolio
-
State Street Corp Boston, MA4.85MShares$118 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.89B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...